Lyon (France) and Cambridge (MA, US), March 11, 2024, at 7:00 a.m. CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against resistant bacterial infections, today announces that the voluntary withdrawal from the Nasdaq Capital Market (“Nasdaq”) of the American Depositary Shares (“ADS”) representing its common shares, is now effective. Each ADS represents one ordinary share of the Company. The Company will file a Form F-15 with the Securities and Exchange Commission (“SEC”) to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (“Exchange Act”), with respect to concerns the ADSs and the underlying ordinary shares. The Company anticipates that the deregistration of the ADSs under the Exchange Act will be effective 90 days after the filing of Form F-15.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]